Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease.

Rizelio V, Szawka RE, Xavier LL, Achaval M, Rigon P, Saur L, Matheussi F, Delattre AM, Anselmo-Franci JA, Meneses M, Ferraz AC.

Braz J Med Biol Res. 2010 Jan;43(1):85-95. Epub 2009 Dec 4.

2.

Intrasubthalamic injection of 6-hydroxydopamine induces changes in the firing rate and pattern of subthalamic nucleus neurons in the rat.

Ni Z, Bouali-Benazzouz R, Gao D, Benabid AL, Benazzouz A.

Synapse. 2001 May;40(2):145-53.

PMID:
11252026
3.

Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.

Marin C, Bonastre M, Mengod G, Cortés R, Rodríguez-Oroz MC, Obeso JA.

Exp Neurol. 2013 Dec;250:304-12. doi: 10.1016/j.expneurol.2013.10.006. Epub 2013 Oct 18.

PMID:
24140562
5.
6.
7.

Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model.

Breit S, Lessmann L, Unterbrink D, Popa RC, Gasser T, Schulz JB.

Eur J Neurosci. 2006 Oct;24(8):2275-82. Epub 2006 Oct 17.

PMID:
17042796
8.

High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.

He Z, Jiang Y, Xu H, Jiang H, Jia W, Sun P, Xie J.

Behav Brain Res. 2014 Apr 15;263:108-14. doi: 10.1016/j.bbr.2014.01.014. Epub 2014 Jan 23.

PMID:
24462728
9.

Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions.

Chen L, Liu Z, Tian Z, Wang Y, Li S.

Stereotact Funct Neurosurg. 2000;75(2-3):66-75.

PMID:
11740172
10.

Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat.

Breit S, Bouali-Benazzouz R, Popa RC, Gasser T, Benabid AL, Benazzouz A.

Exp Neurol. 2007 May;205(1):36-47. Epub 2006 Dec 29.

PMID:
17395181
11.

Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.

Czarnecka A, Lenda T, Domin H, Konieczny J, Smiałowska M, Lorenc-Koci E.

Brain Res. 2013 Dec 6;1541:92-105. doi: 10.1016/j.brainres.2013.10.011. Epub 2013 Oct 12.

PMID:
24129225
12.

Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.

Yoon MC, Shin MS, Kim TS, Kim BK, Ko IG, Sung YH, Kim SE, Lee HH, Kim YP, Kim CJ.

Neurosci Lett. 2007 Aug 9;423(1):12-7. Epub 2007 Jun 28.

PMID:
17644250
13.
14.

Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat's 6-OHDA model of Parkinson's disease.

Winter C, Hosmann K, Harnack D, Meissner W, Paul G, Morgenstern R, Kupsch A.

Synapse. 2006 Jul;60(1):69-80.

PMID:
16598703
15.

Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.

Andringa G, van Oosten RV, Unger W, Hafmans TG, Veening J, Stoof JC, Cools AR.

Eur J Neurosci. 2000 Aug;12(8):3033-43.

PMID:
10971644
16.
17.

Additional noradrenergic depletion aggravates forelimb akinesia and abnormal subthalamic nucleus activity in a rat model of Parkinson's disease.

Wang Y, Chen X, Wang T, Sun YN, Han LN, Li LB, Zhang L, Wu ZH, Huang C, Liu J.

Life Sci. 2014 Dec 5;119(1-2):18-27. doi: 10.1016/j.lfs.2014.10.007. Epub 2014 Nov 1.

PMID:
25445222
18.

Increasing extracellular potassium results in subthalamic neuron activity resembling that seen in a 6-hydroxydopamine lesion.

Strauss U, Zhou FW, Henning J, Battefeld A, Wree A, Köhling R, Haas SJ, Benecke R, Rolfs A, Gimsa U.

J Neurophysiol. 2008 Jun;99(6):2902-15. doi: 10.1152/jn.00402.2007. Epub 2008 Apr 2.

19.
20.

Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway.

Xu L, Chen WF, Wong MS.

Br J Pharmacol. 2009 Oct;158(3):738-48. doi: 10.1111/j.1476-5381.2009.00361.x. Epub 2009 Aug 24.

Supplemental Content

Support Center